This is supported by the previous findings that DNMT3A mutations jointly act with FLT3 and NPM1 mutations to promote resistance to anthracycline chemotherapy54 and that concurrent mutations of DNMT3A, FLT3, and NPM1 have also been associated with poor prognosis of AML patients55. Here, DNMT3A is linked to acute myeloid leukemia.